Impact of pharmaceutical industry involvement in the external review of clinical practice guidelines-A case study

被引:2
|
作者
Bartelmann, Katharina
Gaskins, Matthew
Dressler, Corinna
Nast, Alexander
机构
[1] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergy, Div Evidence Based Med DEBM, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
关键词
clinical practice guideline; dermatology; external review; pharmaceutical industry; quality; S3; GUIDELINE; ACNE;
D O I
10.1111/jep.13166
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Rationale and aim External review is important when developing clinical practice guidelines. Involving pharmaceutical companies may influence guideline recommendations in their favour and is therefore controversial. Our study aimed to measure stakeholder participation in the external review of the 2016 European acne guideline and assess the extent to which comments submitted by pharmaceutical companies suggested changes favouring their own products. Methods Retrospective, partially blinded case study using qualitative analysis of comments submitted during external review. Results Four stakeholder groups participated in the review: pharmaceutical company representatives (five out of five invited), professional association members (2/222), journal reviewers (n = 2), and visitors to the project website (n = 1). Of 78 comments submitted, 48 were from company representatives, 24 from journal reviewers, and six from others. Each comment suggested one change to the guideline. Of the comments submitted by companies, 41.7% related to "writing or formatting," 16.7% to "presentation of results," 12.5% to "background information for main recommendations," and 12.5% to the "strength of treatment recommendation". In 54.2% (26/48) of these comments, a change was suggested that put the companies' own products in a more positive light. Five of these changes were implemented by the guideline authors in the way suggested by the company representatives. Conclusion Participation of professional societies, patients, and the general public in the external review of the 2016 European acne guideline was unacceptably low. This is in concordance with reports of low participation of these groups in other European dermatology guidelines. While involving the pharmaceutical industry in the review substantially increased the number of comments received, many of these sought changes that would have put companies' own products in a more favourable light. Our findings underscore the need to manage reviewer comments in a robust and transparent fashion. Solutions to encourage participation of all relevant stakeholders are needed.
引用
下载
收藏
页码:718 / 727
页数:10
相关论文
共 50 条
  • [1] Industry involvement in clinical practice guidelines
    Lexchin, Joel R.
    CANADIAN FAMILY PHYSICIAN, 2021, 67 (10) : 721 - 724
  • [2] Relationships between authors of clinical practice guidelines and the pharmaceutical industry
    Choudhry, NK
    Stelfox, HT
    Detsky, AS
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (05): : 612 - 617
  • [3] How to incorporate patient perspectives in health technology assessments and clinical practice guidelines-a qualitative study
    Hameen-Anttila, Katri
    Komulainen, Jorma
    Enlund, Hannes
    Makela, Marjukka
    Makinen, Eeva
    Rannanheimo, Piia
    Sipila, Raija
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 : 30 - 30
  • [4] Pharmaceutical industry payments to authors of neurology clinical practice guidelines in Japan: A cross-sectional study
    Murayama, Anju
    Senoo, Yuki
    HEALTH SCIENCE REPORTS, 2024, 7 (09)
  • [5] Patient and public involvement in the development of clinical practice guidelines: a scoping review
    Bryant, Elizabeth Ann
    Scott, Anna Mae
    Greenwood, Hannah
    Thomas, Rae
    BMJ OPEN, 2022, 12 (09):
  • [6] Implementation of Pharmaceutical Practice Guidelines by a Project Model Based Clinical and Economic Impact
    Mahmoudi, Laleh
    Karamikhah, Razieh
    Mahdavinia, Azadeh
    Samiei, Hasan
    Petramfar, Peyman
    Niknam, Ramin
    MEDICINE, 2015, 94 (42) : e1744
  • [7] Clinical practice guidelines A review
    Vachhrajani, Shobhan
    Kulkarni, Abhaya V.
    Kestle, John R. W.
    JOURNAL OF NEUROSURGERY-PEDIATRICS, 2009, 3 (04) : 249 - 256
  • [8] Patient and public involvement in the development of clinical practice guidelines: a scoping review protocol
    Bryant, Elizabeth Ann
    Scott, Anna Mae
    Thomas, Rae
    BMJ OPEN, 2020, 10 (10):
  • [9] Pharmaceutical industry and clinical practice: complementarity and evolution
    Delabarre, Fabrice
    BULLETIN DU CANCER, 2013, 100 (12) : 1231 - 1232
  • [10] ATAC - a case study on the impact of clinical trial data presentations and agency guidelines/technology assessments on clinical practice
    Chlebowski, R.
    BREAST, 2007, 16 : S63 - S63